Franklin Biotechnology Discovery is overseen by experienced managers, but limited resources and an undifferentiated process earn the fund a Morningstar Analyst Rating of Neutral.
NAV / 1-Day Return
113.30 / 0.33 %
Adj. Expense Ratio
Longest Manager Tenure
Investment StyleMid Growth
Min. Initial Investment
Morningstar’s Fund Analysis FTDZX
Will FTDZX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.